AXL and cancer: Second, region-specific ligand–receptor interactions between cancer cells and CAFs—such as ANGPTL4–SDC2, PROS1–AXL, and SEMA4A/D–PLXNB2—have not been systematically validated in large clinical cohorts, and their therapeutic relevance in clinical contexts remains to be determined.